Autoimmune Diseases
Welcome,         Profile    Billing    Logout  
 293 Companies   491 Products   491 Products   198 Mechanisms of Action   26 Trials   7805 News 


«12...1920212223242526272829...156157»
  • ||||||||||  New trial, Surgery, Bariatric surgery:  ThyrBar: Thyroid in Bariatric Surgery (clinicaltrials.gov) -  Feb 9, 2017   
    P=N/A,  N=20, Completed, 
  • ||||||||||  Enrollment closed, Phase classification, Enrollment change, Trial primary completion date:  Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon (clinicaltrials.gov) -  Feb 8, 2017   
    P=N/A,  N=26, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Dec 2016 Recruiting --> Active, not recruiting | Phase classification: P2 --> PN/A | N=35 --> 26 | Trial primary completion date: Dec 2016 --> May 2017
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen
    Trial termination:  Etanercept in Rheumatoid Arthritis and Vascular Inflammation (clinicaltrials.gov) -  Feb 7, 2017   
    P4,  N=5, Terminated, 
    N=24 --> 4 | Suspended --> Terminated | Trial primary completion date: Aug 2017 --> Dec 2015; Company decision Active, not recruiting --> Terminated; Recruitment difficulties
  • ||||||||||  IBC-VS01 / Orban Biotech
    Trial completion:  Evaluation of a Diabetes Vaccine in Newly Diagnosed Diabetics (clinicaltrials.gov) -  Feb 7, 2017   
    P1,  N=12, Completed, 
    Active, not recruiting --> Terminated; Recruitment difficulties No longer recruiting --> Completed
  • ||||||||||  Nucala (mepolizumab) / GSK
    Enrollment closed:  Anti-IL-5 Therapy in Bullous Pemphigoid (BP) (clinicaltrials.gov) -  Feb 7, 2017   
    P2,  N=32, Active, not recruiting, 
    No longer recruiting --> Completed Recruiting --> Active, not recruiting
  • ||||||||||  Trial completion, Trial initiation date:  SisSLE: Autoimmunity in Sisters of Lupus Patients (clinicaltrials.gov) -  Feb 6, 2017   
    P=N/A,  N=817, Completed, 
    Recruiting --> Completed Active, not recruiting --> Completed | Initiation date: Dec 2009 --> Feb 2009
  • ||||||||||  Biomarker, Enrollment closed:  Salivary Biomarkers for Sj (clinicaltrials.gov) -  Feb 6, 2017   
    P=N/A,  N=420, Active, not recruiting, 
    Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting
  • ||||||||||  Enrollment change, Trial withdrawal:  Single Incision Versus Standard Laparoscopic Splenectomy (clinicaltrials.gov) -  Feb 3, 2017   
    P=N/A,  N=0, Withdrawn, 
    Active, not recruiting --> Completed N=30 --> 0 | Active, not recruiting --> Withdrawn
  • ||||||||||  Enrollment open, Phase classification, Trial initiation date, Trial primary completion date:  Task-oriented Circuit Training Combined With Cerebellar tDCS in Multiple Sclerosis Subjects (clinicaltrials.gov) -  Feb 3, 2017   
    P=N/A,  N=30, Recruiting, 
    Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Phase classification: P2 --> PN/A | Initiation date: May 2016 --> Feb 2017 | Trial primary completion date: Dec 2016 --> Jul 2017
  • ||||||||||  Trial completion, Enrollment change:  Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy (clinicaltrials.gov) -  Feb 3, 2017   
    P=N/A,  N=115, Completed, 
    Not yet recruiting --> Recruiting | Phase classification: P2 --> PN/A | Initiation date: May 2016 --> Feb 2017 | Trial primary completion date: Dec 2016 --> Jul 2017 Recruiting --> Completed | N=145 --> 115
  • ||||||||||  Promacta (eltrombopag) / Novartis
    Trial completion, Trial initiation date, Trial primary completion date:  Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) -  Feb 2, 2017   
    P2,  N=12, Completed, 
    Trial primary completion date: Aug 2016 --> Aug 2017 Active, not recruiting --> Completed | Initiation date: May 2009 --> Jan 2009 | Trial primary completion date: Jan 2014 --> Sep 2015
  • ||||||||||  Promacta (eltrombopag) / Novartis
    Trial primary completion date:  End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia (clinicaltrials.gov) -  Feb 2, 2017   
    P=N/A,  N=20, Recruiting, 
    Initiation date: Dec 2016 --> Jun 2017 | Trial primary completion date: Oct 2018 --> Jan 2019 Trial primary completion date: Jun 2013 --> Mar 2019
  • ||||||||||  Enrollment closed, Enrollment change, Trial primary completion date:  Effect of Vitamin D Replacement on Immune Function and Cognition in MS Patients (clinicaltrials.gov) -  Feb 1, 2017   
    P=N/A,  N=108, Active, not recruiting, 
    Initiation date: Jun 2016 --> Jun 2019 Recruiting --> Active, not recruiting | N=86 --> 108 | Trial primary completion date: Aug 2014 --> Jun 2017
  • ||||||||||  Trial completion, Enrollment change:  The Health Log: A Randomized Clinical Trial (clinicaltrials.gov) -  Feb 1, 2017   
    P=N/A,  N=67, Completed, 
    Recruiting --> Active, not recruiting | N=86 --> 108 | Trial primary completion date: Aug 2014 --> Jun 2017 Active, not recruiting --> Completed | N=150 --> 67
  • ||||||||||  VSN16R / Ipsen, University College London
    Trial primary completion date:  Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis (clinicaltrials.gov) -  Jan 31, 2017   
    P2,  N=160, Recruiting, 
    Recruiting --> Completed | N=200 --> 301 Trial primary completion date: Jul 2016 --> Aug 2017
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Trial primary completion date:  Dex/Rituxan: A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone (clinicaltrials.gov) -  Jan 31, 2017   
    P=N/A,  N=50, Recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Jan 2016 --> Jun 2017
  • ||||||||||  amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
    Enrollment closed:  Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients (clinicaltrials.gov) -  Jan 30, 2017   
    P1,  N=17, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting